Hepatitis C Virus seroconversion among persons who inject drugs in relation to primary care physician visiting: The potential role of primary healthcare in a combined approach to Hepatitis C prevention by Roy, Élise
 1 
Hepatitis C Virus seroconversion among persons who inject drugs in relation to primary care 
physician visiting: The potential role of primary healthcare in a combined approach to Hepatitis 
C prevention 
 
Andreea Adelina Artenie a,b, Élise Roy c,d, Geng Zang a, Didier Jutras-Aswad a,e, Jean-Marie 
Bamvita a, Svetlana Puzhko a,b, Mark Daniel f,g, Julie Bruneau a,b,h 
 
a Research Center, Centre hospitalier de l'Université de Montréal (CRCHUM), 900 Saint-Denis, 
Montréal, QC, Canada H2X 0A9 
b Department of Family Medicine, Faculty of Medicine, McGill University, 5858 Chemin de la 
Côte-des-Neiges, Montréal, QC, Canada H3S 1Z1 
c Addiction Research and Study Program, Faculty of Medicine and Health Sciences, Université 
de Sherbrooke, 150 Place Charles-Le Moyne, Longueuil, QC, Canada J4K 0A8 
d Institut National de Santé Publique du Québec, 190 Crémazie E, Montréal, QC, Canada H2P 
1E2 
e Department of Psychiatry, Faculty of Medicine, Université de Montréal, C.P. 6128, succursale 
Centre-ville, Montréal, QC, Canada H3C 3J7 
f School of Population Health, University of South Australia, GPO Box 2471, Adelaide, SA, 
Australia 5001 
g Department of Medicine, St. Vincent’s Hospital, The University of Melbourne, 29 Regent 
Street, Fitzroy, VIC, Australia 3065 
h Department of Family and Emergency Medicine, Faculty of Medicine, Université de Montréal, 
C.P. 6128, succursale Centre-ville, Montréal, QC, Canada H3C 3J7 
 2 
 
CONTACT INFORMATION (CORRESPONDING AUTHOR):  
Julie Bruneau, MD, MSc 
Research Center, Centre Hospitalier de l’Université de Montréal (CRCHUM) 
Tour Viger 
900 Saint-Denis, office R06-434 
Montréal, QC H2X 0A9 
Canada 
Phone: +1 (514) 890-8000 Ext. 35713 · Fax: +1 (514) 412-7280   
E-mail: julie.bruneau@umontreal.ca  
 
 3 
 KEY WORDS: 
Hepatitis C, drug use, injection, primary care, physician, prevention  
 
ABSTRACT:   
Background: Meaningful reductions in Hepatitis C Virus (HCV) transmission rates among 
persons who inject drugs (PWID) require a comprehensive prevention approach, including 
access to harm reduction measures and to healthcare-related interventions, such as HCV 
screening, testing and antiviral treatment. Little is known, however, about the role of visiting a 
primary care physician (PCP) in relation to HCV infection risk among PWID, when integrated 
within a combined prevention approach. This study assessed the association between PCP 
visiting and HCV seroconversion among PWID attending needle exchange programs (NEP).  
Methods: A prospective cohort study, HEPCO, was conducted among active PWID in Montréal 
(2004-2013). Interviews scheduled at three- or six-month intervals included completion of an 
interviewer-administered questionnaire, and collection of blood samples for HCV antibody 
testing. HCV-seronegative participants who reported NEP attendance at baseline and had at least 
one follow-up visit were eligible for this study. HCV incidence was calculated using the person-
time method. Time-varying Cox regression modeling was conducted to evaluate the relationship 
between self-reported recent PCP visiting and HCV incidence.  
Results: At baseline assessment, of 226 participants (80.5% male; median age: 30.6 years), 
37.2% reported having recently visited a PCP. During 449.6 person-years of follow-up, 79 
participants seroconverted to HCV [incidence rate: 17.6 per 100 person-years, 95% confidence 
interval (CI): 14.0-21.8]. Covariate-adjusted analyses indicated that visiting a PCP was 
associated with a lower risk of HCV infection [Adjusted Hazard Ratio: 0.54, 95% CI: 0.31-0.93]. 
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Other independent predictors of HCV infection included unstable housing, cocaine injection and 
prescription opioid injection.  
Conclusion: Among PWID attending NEP, visiting a PCP was associated with a lower risk of 
HCV infection. Yet, only a minority of participants reported PCP visiting. Efforts to intensify 
engagement with PCP among PWID could potentially contribute to lower HCV transmission 
when integrated within a combined approach to prevention. 
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Background  
Injection drug use is the primary driving force behind the spread of Hepatitis C Virus 
(HCV), particularly in developed countries (Hajarizadeh, Grebely, & Dore, 2013). Although 
gradual declines in HCV transmission among persons who inject drugs (PWID) have been 
reported in some settings in recent years, including Vancouver, Canada (Grebely, et al., 2014) 
and Australia (Iversen, Wand, Topp, Kaldor, & Maher, 2013), the incidence of HCV remains 
high [20-25 per 100 person-years (p-y)] in many parts of the world (Leclerc, et al., 2014; Page, 
Morris, Hahn, Maher, & Prins, 2013; Wiessing, et al., 2014). In the SurvUDI network, an 
epidemiologic surveillance network of blood-borne infections among PWID in Eastern Canada, 
the incidence of HCV was estimated at 23.2 per 100 p-y in 2010, a rate that remained relatively 
stable since 1998 (Leclerc, et al., 2014).  
In the absence of a vaccine conferring protection against HCV infection, prevention 
efforts require a strong foundation of harm reduction interventions (Centers for Disease Control 
and Prevention, 2012). Broad access to needle exchange programs (NEP) is considered, by and 
large, a cornerstone measure to an effective HCV prevention response. Sterile syringe provision 
has been shown to play an important role in altering high-risk injection practices, thereby 
potentially reducing the risk of HCV infection (MacArthur, et al., 2014). Access to substance use 
treatment is also considered key in harm reduction. For opiate users, receipt of opiate substitution 
treatment (OST) has been demonstrated to have positive impacts on risky injection behaviours 
(MacArthur, et al., 2014) and more recently, on HCV seroconversion (Nolan, et al., 2014; Tsui, 
Evans, Lum, Hahn, & Page, 2014), though limited evidence exists in support of other addiction 
treatment interventions (e.g., outpatient drug-free programs) (Hagan, Pouget, & Des Jarlais, 
2011). In parallel, timely HCV screening, counseling and testing constitute essential actions for 
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prevention (Centers for Disease Control and Prevention, 2012), as they have the potential to 
impact HCV acquisition and transmission rates by reducing high-risk drug use practices 
(Aspinall, et al., 2014; Bruneau, et al., 2014). Altogether, it is now largely acknowledged that 
substantial reductions in HCV incidence require a comprehensive approach to prevention, 
involving multiple combined strategies (Page, et al., 2013). 
The emphasis on timely HCV screening and testing among high-risk persons has 
included calls for a greater role for primary care physicians (PCP) in HCV prevention and care. 
Clinical reviews (Huffman & Mounsey, 2014; Wong & Lee, 2006) and professional guidelines 
(Public Health Agency of Canada & The College of Family Physicians of Canada, 2009; The 
Royal College of General Practitioners, 2007) on HCV screening, testing, treatment and 
management intended for PCP have served to gradually raise awareness. However, little 
evidence exists to support whether contact with PCP, as part of a combined prevention approach, 
relates to any difference in the incidence of HCV among PWID. 
Previous research has suggested a role for PCP in improving access to HCV assessment 
and harm reduction interventions. Among PWID, contact with PCP has been associated with 
better knowledge surrounding HCV (Treloar, et al., 2011), higher levels of screening and testing 
(Barocas, et al., 2014), and greater interest in treatment initiation for those infected (Strathdee, et 
al., 2005). PCP are also increasingly involved in providing substance use treatment, notably OST 
(Luce & Strike, 2011; Strang, et al., 2005), and contact with primary health care services has 
been linked to lower levels of drug and alcohol use and improved addiction severity among drug-
using populations (Friedmann, Zhang, Hendrickson, Stein, & Gerstein, 2003; Saitz, Larson, 
Horton, Winter, & Samet, 2004).  
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Beyond their role in HCV-specific interventions, PCP, with their focus on 
mainstream health care, can play a broader role in HCV prevention, complementing efforts 
provided through harm reduction strategies. PCP have a well-established role in chronic 
disease prevention (U.S. Preventive Services Task Force, 2014). For Human 
Immunodeficiency Virus (HIV), they have been recognized as having been at the forefront 
of prevention efforts in Australia, and attributes such as whole-person approach to care 
and continuum of care have been identified as key to their contribution (Newman, et al., 
2012).  
The overall aim of this study was to examine the role of visiting a PCP in relation to 
HCV infection among PWID, within a combined prevention approach involving contact with 
NEP. Hence, we investigated the association between PCP visiting and HCV seroconversion 
in a sample of HCV-negative PWID attending NEP in Montréal, Canada.  
Methods 
Study design and participants 
 Participants were selected from the Hepatitis Cohort (HEPCO), a cohort of PWID 
established in November 2004 in Montréal, to examine individual and contextual factors 
associated with HCV transmission. Eligibility criteria for recruitment into HEPCO included self-
reported use of injection drugs in the six-month period prior to the interview, being 18 years of 
age or older, living in the Greater Montréal region and providing informed consent in 
compliance with institutional review board regulations of the Centre Hospitalier de l'Université 
de Montréal. For the purposes of this study, participants were eligible if they reported attending a 
NEP through community-based programs, clinics or pharmacies, at least once in the previous 
six-month period preceding their first assessment. Montréal has a liberal syringe distribution 
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policy, including no limits on the number of syringes and injection kits (cotton, cup, sterile water 
and alcohol pad) that can be obtained. NEP also provide risk reduction counselling and 
references for diverse services, as needed (Leclerc, et al., 2014).  
Cohort recruitment and follow-up procedures have been described in detail previously 
(Bruneau, Roy, Arruda, Zang, & Jutras-Aswad, 2012). Briefly, participants were recruited 
through street-level strategies such as word-of-mouth or community program referrals. Follow-
up visits were scheduled at six-month intervals for the period of November 2004 to March 2011, 
and three-month intervals thereafter. At baseline and at each follow-up visit, participants 
completed a behavioural questionnaire administered by a trained interviewer in a private, face-
to-face setting. The questionnaire elicited information on socio-demographic characteristics, 
drug use patterns and related behaviours, and healthcare services utilization. Venous blood 
samples were drawn for HCV antibody testing at each visit. Participants were asked to return two 
weeks after the interview to obtain their test results, at which point post-test counseling and 
medical referrals were provided as necessary. A CAD 15.00$ honorary was offered to all study 
participants upon completion of the questionnaire.  
Between November 2004 and December 2013, 459 HCV-seronegative participants were 
recruited into HEPCO, of which 283 (61.7%) reported NEP attendance within the six months 
prior to baseline assessment. Of these, 226 participants (79.9%) had at least one follow-up visit 
and were therefore included in the present analyses.  
Measures 
 The outcome of interest was incident HCV infection, determined by the detection of 
HCV antibodies at a follow-up visit among previously HCV-antibody negative participants. 
Blood specimens yielding positive results for HCV antibodies using enzyme immunoassay (EIA, 
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Abbott Laboratories) were confirmed by reverse-transcription polymerase chain reaction (RT-
PCR, Roche Diagnostic Systems). Indeterminate results were subsequently confirmed by dual 
EIA and/or recombinant immunoblot assay (RIBA). The date of HCV seroconversion was 
considered to be the midpoint between the dates of the participants’ visits corresponding to the 
last negative and the first positive HCV test.  
The primary exposure variable was a dichotomous measure assessing whether or not 
participants had visited a PCP working in a clinic or in a local community service center at least 
once in the past six months prior to baseline assessment and between follow-up visits (past six 
months until March 2011, and past three months thereafter). Thorough information on the 
number of visits that were made to PCP was not collected. In Montréal, visits to PCP are free of 
charge, as they are entirely covered by the provincial healthcare insurance. 
Potential confounders included variables previously identified as significant correlates of 
HCV seroconversion among PWID populations, with a prominent focus on those that are most 
important in the Montréal setting where HEPCO participants live (Bruneau, et al., 2012). Socio-
demographic characteristics included age, gender, education and past six-month housing 
arrangements. As previously (Bruneau, et al., 2012), unstable housing was defined as living on 
the street, in shelters or in apartment-hotels rented on a monthly basis (indicating a rapid 
turnover compared to typical 12-month rent–lease accommodation standards in Montréal). Drug 
use patterns and injection practices included past-month cocaine, heroin and prescription opioid 
injection, expressed as dichotomous variables (at least once versus none) and syringe sharing, 
defined as the borrowing of a used syringe at least once in the previous six months. A 
dichotomous variable assessing whether or not participants received methadone maintenance 
therapy in the previous six months was also examined. 
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Except for age, gender and education, all variables were modeled as time-dependent 
covariates. Thus, at any time during follow-up, the values from the visit preceding the date of 
HCV seroconversion or the last completed questionnaire were used. For all statistical tests, the 
significance level was set at 0.05. All statistical analyses were conducted using SAS 9.3 software 
(SAS Institute, Cary, NC).   
Results 
 Two hundred and twenty-six PWID who reported NEP attendance at baseline and had at 
least one follow-up visit were eligible for the present analyses. At baseline assessment, the 
median age of participants was 30.6 years (IQR: 25.7 – 39.4), the majority (80.5%) male, and 
20.4% reported having completed college education. Unstable housing arrangements were 
reported by 48.2%. Eighty-four participants (37.2%) had visited a PCP in the six-month period 
preceding the baseline assessment. With the exception of being slightly younger (median age: 
27.3 versus 30.6, p=0.01) and more likely to inject heroin (57.9% versus 42.9%, p=0.04), 
participants with no follow-up assessments were not statistically significantly different from 
those included in the analyses with regards to socio-demographic characteristics, drug use and 
sharing practices or PCP visiting. 
Table 1 presents the baseline characteristics of participating PWID, stratified according to 
whether or not they had visited a PCP. Compared with PWID who did not visit a PCP, those who 
did so were significantly less likely to be male (71.4% versus 85.9%) and more likely to have 
completed college education (28.6% versus 15.5%). With regards to drug use patterns, they were 
less likely to report cocaine injection (54.8% versus 73.9%).  
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Table 1: Descriptive characteristics at study enrollment of 226 initially HCV-seronegative 
persons who inject drugs attending needle exchange programs in the six months prior, 
stratified by whether or not participants reported past six-month primary care physician 
visiting 
 
 
Category 
Total 
participants 
N=226 
n (%) 
Visited a 
PCP 
N=84 
n (%) 
Did not visit  
a PCP 
N=142 
n (%) 
 
 
p-value a 
Age     
Median 
(IQR) 
30.6 
(25.7 - 39.4) 
31.8  
(26.7 - 41.0) 
30.4  
(25.3 - 38.4) 
0.21 
Gender     
Male 182 (80.5) 60 (71.4) 
122 
(85.9%) 
0.008 
Female 44 (19.5%) 24 (28.6%) 20 (14.1%)  
Completed college education   
Yes 46 (20.4%) 24 (28.6%) 22 (15.5%) 0.018 
No  
180 
(79.6%) 
60 (71.4%) 120 (84.5)  
Unstable housing past six months   
Yes 109 (48.2) 36 (42.9%) 73 (51.4%) 0.214 
No 
117 
(51.8%) 
48 (57.1%) 69 (48.6%)  
Cocaine injection past month   
Yes 
151 
(66.8%) 
46 (54.8%) 
105 
(73.9%) 
0.003 
No 75 (33.2%) 38 (45.2%) 37 (26.1%)  
Heroin injection past month   
Yes 97 (42.9%) 46 (54.8%) 83 (58.5%) 0.588 
No 
129 
(57.1%) 
38 (45.2%) 59 (41.5%)  
Prescription opioid injection past month   
Yes 99 (43.8%) 41 (48.8%) 58 (40.8%) 0.244 
No  
127 
(56.2%) 
43 (51.2%) 84 (59.2%)  
Syringe sharing past six months   
Yes 64 (28.3%) 26 (31.0%) 38 (26.8%) 0.499 
 No  
162 
(71.7%) 
58 (69.0%) 
104 
(73.2%) 
 
Methadone maintenance treatment past six months  
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Figure 1: Kaplan-Meier survival curve for Hepatitis C Virus seroconversion among 226 
initially HCV-seronegative persons who inject drug reporting past six-month needle 
exchange program attendance at baseline assessment, stratified by whether or not 
participants reported having visited a primary care physician  
 
  
 
 Table 2 presents unadjusted and adjusted HR for the associations between visiting a PCP, 
socio-demographic and behavioural characteristics, and the risk of HCV seroconversion. In 
univariate Cox regression analyses, visiting a PCP was associated with a 0.52 lower risk of HCV 
seroconversion. In addition, unstable housing, cocaine injection, prescription opioid injection and 
syringe sharing were associated with a greater risk of HCV infection. In the multivariate Cox 
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regression analyses, visiting a PCP remained independently associated with a lower risk of HCV 
seroconversion (HR: 0.54, 95% CI: 0.31 - 0.93). Other variables that remained independently 
associated with incident HCV infection included unstable housing (HR: 2.08, 95% CI: 1.26 – 
3.43), cocaine injection (HR: 2.96, 95% CI: 1.66 – 5.27) and prescription opioid injection (HR: 
2.31, 95% CI: 1.41 – 3.78). 
 
Table 2: Univariate and covariate-adjusted associations with HCV seroconversion among 
226 initially HCV-seronegative persons who inject drugs reporting needle exchange 
program attendance at baseline assessment, by Cox proportional hazards regression 
analyses 
Variable 
 
Unadjusted 
HR 
95% CI 
 
Adjusted 
HR 
95% CI 
Visited a PCP past six months 0.52 0.31 - 0.89 0.54 0.31 - 0.93 
Age (per 5-year older) 0.94 0.83 - 1.06 0.96 0.84 - 1.10 
Male gender 0.9 0.51 - 1.58 0.55 0.30 - 1.02 
Completed college education 0.62 0.33 - 1.18   
Unstable housing past six 
months 
2.61 1.65 - 4.13 2.08 1.26 - 3.43 
Cocaine injection past month 3.36 1.90 - 5.93 2.96 1.66 - 5.27 
Heroin injection past month 1.47 0.94 - 2.29   
Prescription opioid injection 
past month 
2.81 1.78 - 4.42 2.31 1.41 - 3.78 
Syringe sharing past six 
months 
1.81 1.14 - 2.87   
Methadone maintenance 
treatment past six months 
0.91 0.55 - 1.53     
 
Abbreviations: PCP, primary care physician; HR, hazard ratio; CI, confidence interval 
 
 16 
Discussion  
Our results indicate markedly lower HCV seroconversion rates among NEP-attending 
PWID in Montréal who visited a PCP compared to those who did not report doing so. Further, in 
multivariate analyses adjusting for known confounders, visiting a PCP remained independently 
associated with a nearly 50% lower risk of HCV infection. To our knowledge, this is the first 
time that the impact of PCP visiting in relation to HCV seroconversion has been examined. This 
finding aligns with, and supports a growing emphasis on the role of PCP in HCV prevention.  
The observed lower risk of incident HCV infection among PWID attending NEP who 
visited a PCP could reflect a response to a multi-faceted prevention approach. Typically, in 
addition to providing sterile injection equipment, contact with NEP offers an opportunity for 
ongoing education and risk behaviour counseling. Visits to PCP are likely to reinforce and add to 
HCV prevention efforts offered through harm reduction programs like NEP. It is possible that 
our finding is attributed to increased evaluation with regards to HCV, as previous studies have 
illustrated that PWID who have been in contact with a PCP were more knowledgeable about 
HCV (Treloar, et al., 2011) and more likely to have received HCV screening and testing 
(Barocas, et al., 2014). Primary health care settings foster continuity of care and the development 
of familiarity and trust between PWID and their PCP (Hopwood & Treloar, 2013). These factors 
have been shown to encourage PWID’s engagement in the HCV assessment process, as they feel 
more comfortable seeking and receiving information regarding HCV (Swan, et al., 2010). For 
PWID who have visited their PCP, timely HCV screening and counseling may have had a 
positive impact on the adoption of risky injection practices (Aitken, Kerger, & Crofts, 2002; 
Bruneau, et al., 2014). 
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The observed lower risk of HCV acquisition among participants reporting PCP visiting 
may also be partly attributed to increased assessment and intervention with regards to drug and 
alcohol problems, and greater access to mainstream healthcare. PCP are increasingly involved in 
providing treatment for substance use (Strang, et al., 2005), and contact with primary health care 
services has been shown to be associated with improved addiction-related outcomes (Friedmann, 
et al., 2003; Saitz, et al., 2004). Although our finding does not appear to be mediated by 
exposure to OST, it is noteworthy that a high proportion of participants were mainly cocaine-
users, and therefore, not eligible for this type of therapy. Access to substance use treatment other 
than OST may have played a role (Hagan, et al., 2011), although our data did not permit detailed 
assessment of this possibility. More broadly, it is possible that access to timely assessment and 
management of co-morbidities through ongoing care may have encouraged some PWID to 
modify their perception of themselves, leading them to identify with ordinary patients rather than 
with “simply drug users” (Jauffret-Roustide, et al., 2012). This change in perception may have 
added, in turn, an important motivational element to their concern with their general health, 
possibly prompting them to engage in safer injection practices (Jauffret-Roustide, et al., 2012).  
Although our finding illustrates that contacts with PCP in combination with access to 
NEP can potentially play an important role in reducing HCV transmission rates among PWID, 
only slightly more than a third (37.2%) of NEP attendees reported having visited a PCP. This 
low proportion suggests an inadequate level of communication between harm reduction 
programs and primary healthcare, despite recommendations regarding the importance of 
coordinating care services for PWID (Centers for Disease Control and Prevention, 2012). In 
Montréal, NEP do not typically have PCP directly affiliated to their service. In addition, the late 
operating-hour system prevailing among NEP may result in fewer opportunities to establish 
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direct linkage with primary healthcare services, which typically function during daytime hours. 
One strategy to overcome this division of services and foster timely engagement in primary care 
among PWID would be to integrate PCP within NEP (Islam, Topp, Day, Dawson, & Conigrave, 
2012). Similarly, outreach workers such as street nurses may also contribute to enhancing 
linkage with primary healthcare services in this population (Artenie, et al., 2015).  
Consistent with previous studies (Grebely, et al., 2014; Kim, et al., 2009), unstable 
housing was associated with an elevated risk of HCV seroconversion among PWID. Greater 
exposure to risky injection practices among PWID who are unstably-housed, such as injecting in 
public spaces, has been put forward as a possible explanation for this finding (Kim, et al., 2009). 
Cocaine and prescription opioid injection were also found to be associated with an elevated risk 
of HCV acquisition in our study. The link between cocaine injection and HCV transmission risk 
is well documented (Bruneau, et al., 2012; Grebely, et al., 2014), this finding attributed mainly to 
the greater likelihood of exposure to contaminated blood as a result of high injection frequency 
during “binge days” (up to 30 times per day) (Bux, Lamb, & Iguchi, 1995). More recently, our 
group showed that injection of prescription opioids is an independent risk factor for HCV 
transmission among PWID (Bruneau, et al., 2012). The repeated number of injections required to 
administer a single dose of prescribed opioids coupled with specific social practices prevailing 
among PWID injecting prescription opioids, such as sharing of potentially contaminated drug 
residues, have been proposed as possible explanations for the greater risk of HCV transmission 
in this sub-group (Roy, Arruda, & Bourgois, 2011). Syringe sharing did not remain significantly 
associated with HCV acquisition when adjusted for other covariates. This suggests that HCV 
exposure through cocaine and prescription opioid drug injection patterns may outweigh the risk 
of HCV acquisition through syringe sharing in our study.  
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Our study is subject to a number of limitations. Similar to most studies involving illicit 
drug-using populations, participants were not randomly recruited into the study, thereby limiting 
the generalisability of our findings. Yet, the socio-demographic and drug use characteristics of 
the HEPCO participants are, by and large, reflective of the PWID population in Québec (Public 
Health Agency of Canada, 2006). Although follow-up was high for a drug-using population, and 
few differences were found between participants retained in the study and those lost since their 
first visit, there is still a possibility that our findings are influenced by losses to follow-up. 
Further, since data for this study were collected through self-report, social desirability bias might 
arise as a result of eliciting information on socially sensitive behaviour. However, self-reported 
data collected from drug-using populations appear to be generally reliable and valid (Darke, 
1998). As with all cohort studies, residual confounding of our results due to unmeasured factors 
associated with HCV-seroconversion is a possibility. For instance, it may be that participants 
who visited a PCP were more likely to engage in harm reduction and HCV prevention programs 
relative to participants who did not indicate PCP visiting. Yet, it is noteworthy that, at baseline 
assessment, we did not find any difference between participants who did and did not report PCP 
visiting with regards to receipt of OST. Lastly, as this study relied on secondarily collected data, 
the absence of information detailing the number of visits made to PCP precluded assessment of a 
potential dose-response relationship between PCP visiting and risk of HCV-seroconversion. 
In summary, our results indicate, for the first time, that contact with PCP as part of a 
combined HCV prevention approach involving attendance at NEP, is associated with a lower risk 
of HCV acquisition among PWID. Future research is needed to examine which interventions, as 
delivered by PCP, are responsible for the observed lesser extent of HCV seroconversion. 
Furthermore, while our findings are encouraging, the extent of communication and interaction 
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between NEP and PCP seems insufficient, suggesting that steps be taken to enhance dialogue 
between harm reduction and primary healthcare services. 
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